ClinicalTrials.Veeva

Menu

Effect of Renal Denervation on NO-mediated Sodium Excretion and Plasma Levels of Vasoactive Hormones (RENO)

R

Regional Hospital Holstebro

Status

Unknown

Conditions

Essential Hypertension

Treatments

Drug: NG-monomethyl-L-arginine (L-NMMA)

Study type

Interventional

Funder types

Other

Identifiers

NCT01617551
RENO_01

Details and patient eligibility

About

Catheter based renal denervation (CRD) in humans represents a promising new treatment of resistant hypertension. CRD is currently investigated as a treatment option in patients with resistant hypertension defined as at least 3 antihypertensive drugs (including a diuretic) in a randomized, sham-controlled, multicenter trial in Denmark (ReSet). In ReSet, patients are randomized to either CRD or a sham procedure with 6 months follow up. The mechanisms by which CRD reduce blood pressure are only partly understood and the interaction between renal sympathetic nerves and nitric oxide (NO) has not been investigated in humans.

To Study the interaction between NO and renal sympathetic nerves, we designed the present substudy, where the effects of NO-inhibition on renal, hemodynamic and hormonal variables are studied before and after CRD.

Enrollment

30 estimated patients

Sex

All

Ages

30 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 30-70 years
  • Stable antihypertensive treatment for 1-month with at least 3 antihypertensive drugs including a diuretic
  • Day-time ambulatory blood pressure > 145/75 mmHg

Exclusion criteria

  • Non compliance
  • Pregnancy/no-anticonception in fertile women
  • Radiocontrast allergy
  • Malignancy
  • Congestive heart failure (EF < 50)
  • eGFR < 45
  • Unstable angina pectoris
  • Recent myocardial infarction or PCI (< 6 mdr)
  • Secondary hypertension
  • Renal artery stenosis or multiple renal arteries on CT
  • Claudication

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

30 participants in 2 patient groups

Renal denervation
Experimental group
Description:
Patient group randomized to renal denervation
Treatment:
Drug: NG-monomethyl-L-arginine (L-NMMA)
Sham
Sham Comparator group
Description:
Patients randomized to sham procedure
Treatment:
Drug: NG-monomethyl-L-arginine (L-NMMA)

Trial contacts and locations

1

Loading...

Central trial contact

Jesper N Bech, MD, Ph.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems